Replies to post #62833 on Biotech Values

[DewDiligence]

>VRTX – if SGP's Phase 3 is sufficient for a registration strategy in the second line, then why should VRTX have to run a greater burden since Prove 3 is already larger and more comprehensive…<

SGP’s phase-3 trial in the second line ('RESPOND-2') will not be sufficient for approval all by itself, IMO.

p.s. Thanks for the pointer on which webcasts to listen to.

[DewDiligence]

>SGP VRTX – Could very well be that the FDA required 28 week treatment [in the SPRINT-2 treatment-naïve trial] and it will juxtapose against 48 week treatment given the present data out of boceprevir.<

Regardless of whether the FDA required a 28-week arm in SPRINT-2, it clearly benefits SGP to include such an arm.